Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI)
|Original title:||Adiponectin, its cardioprotective effects and genetic variability in relation to restenosis after percutaneous coronary intervention (PCI)|
|Authors:||Julie Bienertová Vašků, Petr Bienert, Anna Vašků|
|Field:||Cardiovascular diseases incl. cardiosurgery|
|Type:||Chapter of a book|
|Keywords:||adiponectin; percutaneous coronary intervention; restenosis; polymorphism|
Restenosis after percutaneous coronary intervention (PCI) represents a major limitation to this procedure and despite large efforts it is still difficult to stratify patients after PCI according to restenosis risk. A wide range of proteins have been investigated in order to establish new diagnostic/prognostic markers of restenosis after PCI, without major effects. Adiponectin, a protein secreted exclusively by the adipose tissue, has recently emerged as an anti-inflammatory, anti-atherogenic, insulin-sensitizing factor providing possible link between white adipose tissue and cardiovascular disease. This crucial role in cardioprotection is mediated via a variety of mechanisms, including inhibition of foam cell formation, expression of antithrombogenic properties and inhibition of smooth muscle cells proliferation, all vital processes in restenosis development. Considering its cardioprotective effects, the role of adiponectin in prediction of adverse cardiovascular events has been studied extensively. However, little attention is paid to adiponectin role in restenosis development after PCI, even though pathophysiology of restenosis covers directly the mechanisms regulated or substantially influenced by adiponectin. The current review describes pathophysiological effects of adiponectin in cardiovascular system, mainly those closely associated with restenosis development and attention is being paid also to the role of genetic variability.